Aims Nebivolol is a selective β1‐receptor antagonist with vasodilating properties. In patients
with essential hypertension, we tested the hypothesis that nebivolol increases systemic and …

Nebivolol is a new selective beta 1‐adrenoceptor antagonist with nitric oxide (NO)–
releasing properties. In the present study we have analyzed whether nebivolol affects the …

Objectives: Nebivolol is a selective β 1-adrenoceptor antagonist with endothelium-mediated
vasodilating properties. The effects of nebivolol on renal haemodyamics are unknown in …

Background: Nebivolol is a selective β1-adrenergic receptor antagonist that causes a direct
vasodilator effect attributed to the action on vascular nitric oxide (NO). This study aimed to …

Background Vascular endothelial dysfunction may predict future atherosclerosis. Hence, an
antihypertensive agent that reverses endothelial dysfunction and lowers blood pressure …

Background Nebivolol is a new β 1-selective adrenergic receptor antagonist with a direct
vasorelaxant effect that involves activation of the l-arginine–nitric oxide (NO) pathway …

Background. Nitric oxide (NO) deficiency contributes to chronic kidney disease (CKD)
progression and hypertension. The β-blocker, nebivolol (N), also enhances NO production …

β-blockers are among the most widely used drugs in the prevention and treatment of
cardiovascular disease, although they are associated with increased peripheral resistance …

New evidence from recently completed clinical studies performed with nebivolol, a highly
selective beta‐1 β‐blocker, endowed with additional vasodilating activity mediated by nitric …

Reactive oxygen species play an important role in both acute and chronic kidney diseases.
Chronic kidney disease is associated with various consequences to the cardiovascular …